Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
European Journal of Clinical Pharmacology|February 26, 2022
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin geneDavid A Nielsen, Robrina Walker, David P Graham, et al.
The New England Journal of Medicine|March 31, 2016
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice OffendersJoshua D Lee, Peter D Friedmann, Timothy W Kinlock, et al.
JAMA Network Open|January 25, 2022
Perspectives About Emergency Department Care Encounters Among Adults With Opioid Use DisorderKathryn Hawk, Ryan McCormack, E Jennifer Edelman, et al.
JAMA Psychiatry|October 4, 2023
Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder TreatmentSean X Luo, Daniel J Feaster, Ying Liu, et al.
JAMA Network Open|May 20, 2021
Comparison of Methods for Alcohol and Drug Screening in Primary Care ClinicsJennifer McNeely, Angéline Adam, John Rotrosen, et al.
Lancet (London, England)|November 19, 2017
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
Addiction (Abingdon, England)|March 8, 2016
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) studyWalter Ling, Maureen P Hillhouse, Andrew J Saxon, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
European Journal of Clinical Pharmacology|February 26, 2022
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin geneDavid A Nielsen, Robrina Walker, David P Graham, et al.
The New England Journal of Medicine|March 31, 2016
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice OffendersJoshua D Lee, Peter D Friedmann, Timothy W Kinlock, et al.
JAMA Network Open|January 25, 2022
Perspectives About Emergency Department Care Encounters Among Adults With Opioid Use DisorderKathryn Hawk, Ryan McCormack, E Jennifer Edelman, et al.
JAMA Psychiatry|October 4, 2023
Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder TreatmentSean X Luo, Daniel J Feaster, Ying Liu, et al.
JAMA Network Open|May 20, 2021
Comparison of Methods for Alcohol and Drug Screening in Primary Care ClinicsJennifer McNeely, Angéline Adam, John Rotrosen, et al.
Lancet (London, England)|November 19, 2017
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
Addiction (Abingdon, England)|March 8, 2016
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) studyWalter Ling, Maureen P Hillhouse, Andrew J Saxon, et al.
Pageof 16